Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 15 mcgHA/Strain/0.5mL) for the Use in the Season 2013/2014 in Adult and Elderly Subjects

Trial Profile

Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 15 mcgHA/Strain/0.5mL) for the Use in the Season 2013/2014 in Adult and Elderly Subjects

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2017

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors Fluart Innovative Vaccines
  • Most Recent Events

    • 19 Oct 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top